Searching…
Mar 9, 2022 · STELLAR is a multicenter, open-label, randomized phase III study. STELLAR was designed by the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical C...
Nov 15, 2025 · STELLAR-303 is the first phase 3 trial to show a significant improvement in overall survival with an immunotherapy-based regimen, zanzalintinib–atezolizumab, in patients with relapsed or refractory meta...
Jul 23, 2024 · Presented is the design of STELLAR-303, a global, phase III, open-label, randomized study evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with non-MSI-H mCRC who progressed dur...
May 4, 2025 · Vienna, Austria — A new STELLAR II trial presented at ESTRO 2025 reveals that adding immunotherapy to standard radiotherapy and chemotherapy significantly boosts the rate of complete tumour disappearance...
May 29, 2025 · 近期发表在《国际放射肿瘤学杂志》（International Journal of Radiation Oncology）上的一项研究，对STELLAR III期临床试验进行了长达6年的随访分析。 这项研究旨在比较 全新辅助治疗 与 同步放化疗 在 直肠癌 患者生活质量和肛门功能方面的长期差异。
May 5, 2025 · 该研究的5年数据进一步证实了SCRT序贯新辅助化疗的TNT策略在改善疗效的稳定优势，为中低位局部晚期直肠癌（LARC），特别是高危患者提供了更优的治疗选择。作为STELLAR系列的重要延续，STELLARII…
Jun 25, 2025 · STELLAR II 研究 II 期结果：iTNT 方案进一步提高 CR 率，安全性可控 作为STELLAR系列的重要延续，STELLAR II研究在免疫治疗时代背景下，基于STELLAR研究所确立的TNT方案上，进一步探索了是否联合PD-1单抗治疗（iTNT）能够改善LARC患者的治疗效果。
